| A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis N Ruperto, DJ Lovell, R Cuttica, N Wilkinson, P Woo, G Espada, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2007 | 509 | 2007 |
| National Health and Nutrition Examination Survey, 2015− 2018: sample design and estimation procedures TC Chen, J Clark, MK Riddles, LK Mohadjer, THI Fakhouri | 466 | 2020 |
| Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with … HI Hurwitz, N Uppal, SA Wagner, JC Bendell, JT Beck, SM Wade III, ... Journal of Clinical Oncology 33 (34), 4039-4047, 2015 | 307 | 2015 |
| First-in-human phase I study of the oral inhibitor of indoleamine 2, 3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies GL Beatty, PJ O'Dwyer, J Clark, JG Shi, KJ Bowman, PA Scherle, ... Clinical Cancer Research 23 (13), 3269-3276, 2017 | 299 | 2017 |
| National Health and Nutrition Examination Survey, 2017–March 2020 prepandemic file: sample design, estimation, and analytic guidelines. LJ Akinbami, TC Chen, O Davy, CL Ogden, S Fink, J Clark, MK Riddles, ... | 252 | 2022 |
| National health and nutrition examination survey: estimation procedures, 2011–2014 TC Chen, JD Parker, J Clark, HC Shin, JR Rammon, VL Burt | 158 | 2018 |
| National Health and Nutrition Examination Survey: estimation procedures, 2007-2010. LB Mirel, LK Mohadjer, SM Dohrmann, J Clark, VL Burt, CL Johnson, ... Vital and health statistics. Series 2, Data evaluation and methods research …, 2013 | 139 | 2013 |
| Integrating predictive biomarkers and classifiers into oncology clinical development programmes RA Beckman, J Clark, C Chen Nature reviews Drug discovery 10 (10), 735-748, 2011 | 131 | 2011 |
| A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid … F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ... Clinical Cancer Research 17 (19), 6304-6312, 2011 | 130 | 2011 |
| Cancelled operations: a 7-day cohort study of planned adult inpatient surgery in 245 UK National Health Service hospitals DJN Wong, SK Harris, SR Moonesinghe, SR Moonesinghe, DJN Wong, ... British journal of anaesthesia 121 (4), 730-738, 2018 | 118 | 2018 |
| Evidence-Based Guideline on Laparoscopy in Pregnancy:[image][image]: Commissioned by the British Society for Gynaecological Endoscopy (BSGE): Endorsed by the Royal College of … E Ball, N Waters, N Cooper, C Talati, R Mallick, S Rabas, A Mukherjee, ... Facts, views & vision in ObGyn 11 (1), 5, 2019 | 111 | 2019 |
| Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors AM Traynor, M Hewitt, G Liu, KT Flaherty, J Clark, SJ Freedman, BB Scott, ... Cancer chemotherapy and pharmacology 67, 305-314, 2011 | 110 | 2011 |
| Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis JO Mascarenhas, M Talpaz, V Gupta, LM Foltz, MR Savona, R Paquette, ... Haematologica 102 (2), 327, 2017 | 105 | 2017 |
| Ruxolitinib+ capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies H Hurwitz, E Van Cutsem, J Bendell, M Hidalgo, CP Li, MG Salvo, ... Investigational new drugs 36, 683-695, 2018 | 104 | 2018 |
| Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index G Harding, D Cella, D Robinson, PJ Mahadevia, J Clark, DA Revicki Health and Quality of Life Outcomes 5, 1-12, 2007 | 97 | 2007 |
| Hereditary hyperferritinemia-cataract syndrome: prevalence, lens morphology, spectrum of mutations, and clinical presentations JE Craig, JB Clark, JL McLeod, MA Kirkland, G Grant, JE Elder, ... Archives of ophthalmology 121 (12), 1753-1761, 2003 | 90 | 2003 |
| MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia FJ Giles, RT Swords, A Nagler, A Hochhaus, OG Ottmann, DA Rizzieri, ... Leukemia 27 (1), 113-117, 2013 | 86 | 2013 |
| A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia JF Seymour, DW Kim, E Rubin, A Haregewoin, J Clark, P Watson, ... Blood cancer journal 4 (8), e238-e238, 2014 | 78 | 2014 |
| A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients EH Rubin, GI Shapiro, MN Stein, P Watson, D Bergstrom, A Xiao, JB Clark, ... Journal of Clinical Oncology 24 (18_suppl), 3009-3009, 2006 | 71 | 2006 |
| A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic … H Hurwitz, N Uppal, SA Wagner, JC Bendell, JT Beck, S Wade, ... Journal of Clinical Oncology 32 (15_suppl), 4000-4000, 2014 | 70 | 2014 |
